Back to top

messenger-rna: Archive

Zacks Equity Research

Why Moderna (MRNA) Stock Price Was Up 9% on Monday

Moderna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous squamous cell carcinoma, a form of skin cancer.

MRKNegative Net Change MRNAPositive Net Change ANIPPositive Net Change ADMAPositive Net Change

Zacks Equity Research

Moderna (MRNA) Beats on Q4 Earnings & Sales, Reiterates View

Moderna (MRNA) beats expectations for earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

MRKNegative Net Change MRNAPositive Net Change ACETNegative Net Change PBYIPositive Net Change

Zacks Equity Research

Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.

MRKNegative Net Change MRNAPositive Net Change ARQTPositive Net Change CGEMPositive Net Change

Zacks Equity Research

Can Moderna's (MRNA) Launches Reduce COVID Sales Dependency?

With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next five years.

PFENegative Net Change MRKNegative Net Change MRNAPositive Net Change